MA51431B1 - Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase - Google Patents

Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Info

Publication number
MA51431B1
MA51431B1 MA51431A MA51431A MA51431B1 MA 51431 B1 MA51431 B1 MA 51431B1 MA 51431 A MA51431 A MA 51431A MA 51431 A MA51431 A MA 51431A MA 51431 B1 MA51431 B1 MA 51431B1
Authority
MA
Morocco
Prior art keywords
oxy
kinase inhibitor
derivatives used
fluoropiperidine
fluoropiperidine derivatives
Prior art date
Application number
MA51431A
Other languages
English (en)
Other versions
MA51431A (fr
Inventor
Sun Ah Jun
In Woo Kim
Nam Youn Kim
Jun Hee Lee
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MA51431A publication Critical patent/MA51431A/fr
Publication of MA51431B1 publication Critical patent/MA51431B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne un composé représenté par la formule chimique 1 suivante, ou un sel pharmaceutiquement acceptable de celui-ci, et le composé selon la présente invention peut être utilement utilisé pour la prévention ou le traitement de maladies qui sont associées à des actions inhibitrices de kinase.
MA51431A 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase MA51431B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (fr) 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Publications (2)

Publication Number Publication Date
MA51431A MA51431A (fr) 2021-04-07
MA51431B1 true MA51431B1 (fr) 2022-08-31

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51431A MA51431B1 (fr) 2017-12-28 2018-12-28 Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase

Country Status (32)

Country Link
US (1) US11339167B2 (fr)
EP (1) EP3733673B1 (fr)
JP (1) JP6995428B2 (fr)
KR (2) KR102318929B1 (fr)
CN (1) CN111527091B (fr)
AU (1) AU2018394997B2 (fr)
BR (1) BR112020013141B1 (fr)
CA (1) CA3084962C (fr)
CL (1) CL2020001752A1 (fr)
CO (1) CO2020007162A2 (fr)
DO (1) DOP2020000112A (fr)
EC (1) ECSP20035590A (fr)
ES (1) ES2922633T3 (fr)
HR (1) HRP20221043T1 (fr)
HU (1) HUE059580T2 (fr)
IL (1) IL275207B (fr)
LT (1) LT3733673T (fr)
MA (1) MA51431B1 (fr)
MX (1) MX2020006799A (fr)
MY (1) MY194468A (fr)
NZ (1) NZ764644A (fr)
PE (1) PE20201146A1 (fr)
PH (1) PH12020551013A1 (fr)
PL (1) PL3733673T3 (fr)
PT (1) PT3733673T (fr)
RS (1) RS63515B1 (fr)
RU (1) RU2758370C1 (fr)
SA (1) SA520412335B1 (fr)
SG (1) SG11202004917UA (fr)
SI (1) SI3733673T1 (fr)
TN (1) TN2020000082A1 (fr)
WO (1) WO2019132562A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CA3084962C (fr) * 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Derives d'oxy-fluoropiperidine utilises en tant qu'inhibiteur de kinase
EP3914348A1 (fr) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine,1,2,4-triazolo[4,3-a]pyridine et imidazo[1,5-a]pyrazine utilisées en tant qu'inhibiteurs de jak
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
CN115023428A (zh) * 2020-01-21 2022-09-06 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2021147953A1 (fr) * 2020-01-21 2021-07-29 江苏先声药业有限公司 Dérivé cyclique pyrimidino à cinq chaînons et application correspondante
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (fr) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 Composé hétérocyclique contenant de l'azote et son utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2009026107A1 (fr) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Inhibiteurs de protéine kinases
WO2009131687A2 (fr) * 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibiteurs de protéines kinases
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN102947316B (zh) 2010-06-23 2016-08-10 韩美科学株式会社 用于抑制酪氨酸激酶活性的新型稠合嘧啶衍生物
UA110259C2 (uk) 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину
KR102181365B1 (ko) 2012-08-06 2020-11-23 에이시아 바이오사이언시스 인코포레이티드. 단백질 키나아제 억제제로서 새로운 피롤로피리미딘 화합물
CA2897985A1 (fr) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Composes de type pyrrolopyrimidine substituee, compositions en contenant et methodes de traitement faisant appel a eux
US9469644B2 (en) 2013-03-05 2016-10-18 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
CA2924362C (fr) * 2013-09-18 2018-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. Compose inhibiteur d'activites de kinase de btk et/ou de jak3
CN107417684A (zh) 2013-12-05 2017-12-01 辉瑞公司 杂环丙烯酰胺
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
MX2021009378A (es) * 2016-06-30 2022-06-29 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CA3084962C (fr) * 2017-12-28 2022-08-09 Daewoong Pharmaceutical Co., Ltd. Derives d'oxy-fluoropiperidine utilises en tant qu'inhibiteur de kinase
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
EP3733673A4 (fr) 2021-06-09
SA520412335B1 (ar) 2022-09-19
PL3733673T3 (pl) 2022-09-26
BR112020013141A2 (pt) 2021-02-23
TN2020000082A1 (en) 2022-01-06
WO2019132562A1 (fr) 2019-07-04
US11339167B2 (en) 2022-05-24
CL2020001752A1 (es) 2020-11-27
PE20201146A1 (es) 2020-10-26
CA3084962C (fr) 2022-08-09
CN111527091B (zh) 2023-03-28
EP3733673B1 (fr) 2022-06-29
ES2922633T3 (es) 2022-09-19
EP3733673A1 (fr) 2020-11-04
MX2020006799A (es) 2020-09-03
KR102318929B1 (ko) 2021-10-28
AU2018394997B2 (en) 2021-02-04
LT3733673T (lt) 2022-08-10
RS63515B1 (sr) 2022-09-30
AU2018394997A1 (en) 2020-06-11
BR112020013141B1 (pt) 2022-03-15
CN111527091A (zh) 2020-08-11
KR20210062618A (ko) 2021-05-31
DOP2020000112A (es) 2020-08-31
IL275207A (en) 2020-07-30
PT3733673T (pt) 2022-07-18
MY194468A (en) 2022-11-30
JP6995428B2 (ja) 2022-01-14
SI3733673T1 (sl) 2022-09-30
NZ764644A (en) 2023-06-30
HRP20221043T1 (hr) 2022-11-11
KR102592083B1 (ko) 2023-10-20
US20200308177A1 (en) 2020-10-01
SG11202004917UA (en) 2020-06-29
CA3084962A1 (fr) 2019-07-04
ECSP20035590A (es) 2020-07-31
IL275207B (en) 2022-09-01
HUE059580T2 (hu) 2022-11-28
MA51431A (fr) 2021-04-07
PH12020551013A1 (en) 2021-08-16
KR20190080803A (ko) 2019-07-08
JP2021506818A (ja) 2021-02-22
RU2758370C1 (ru) 2021-10-28
CO2020007162A2 (es) 2020-06-19

Similar Documents

Publication Publication Date Title
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA46337B1 (fr) Composé de pyridine
MA52948B1 (fr) Composés
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA47469B1 (fr) Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
PH12021550743A1 (en) Boron containing pde4 inhibitors
MA39983A (fr) Dérivés de carboxamide
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA43231B1 (fr) Bloqueur des canaux sodiques
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA46965B1 (fr) Modulateurs de gamma ror (rory)
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
MA45855B1 (fr) Nouvelle utilisation du n, n-bis-2-mercaptoéthyle isophtalamide
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
EA201992397A1 (ru) Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam